Vonoprazan Triple and Reverse Hybrid Regimens Outperform High-Dose Dual Therapy for H. pylori : AJG | May 2026

Introduction

Helicobacter pylori Infection remains a major global cause of peptic ulcer disease, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Rising antimicrobial resistance, particularly to clarithromycin, has progressively reduced eradication success with conventional triple therapy. The introduction of Vonoprazan has renewed interest in simplified high-acid suppression regimens capable of improving eradication rates.

Problem Statement

The optimal first-line vonoprazan-based eradication strategy remains uncertain, particularly regarding whether simplified high-dose dual therapy can achieve efficacy comparable to more complex triple or hybrid regimens in regions with substantial antibiotic resistance.

Summary

This multicenter Taiwanese randomized trial compared three contemporary first-line eradication strategies for H. pylori infection: vonoprazan high-dose dual therapy, vonoprazan triple therapy and rabeprazole-based reverse hybrid therapy over 14 days.

The study demonstrated that both vonoprazan triple therapy and rabeprazole reverse hybrid therapy achieved significantly superior eradication rates compared with vonoprazan high-dose dual therapy. Intention-to-treat eradication exceeded 89% with the triple and reverse hybrid regimens, whereas vonoprazan dual therapy achieved lower efficacy at approximately 84%.

These findings are clinically important because simplified dual therapies have been increasingly promoted as antibiotic-sparing approaches intended to reduce antimicrobial exposure and resistance selection. However, the results suggest that dual therapy may be insufficient in regions with significant clarithromycin resistance or heavier bacterial burden.

Notably, adverse event rates were relatively low and comparable across all treatment groups, indicating that the improved efficacy of the more intensive regimens was not offset by substantially worse tolerability. This supports the clinical practicality of triple and reverse hybrid approaches in routine first-line management.

The study also identified several important predictors of eradication failure. Clarithromycin resistance emerged as a major determinant of treatment failure, reinforcing the continuing global challenge posed by antimicrobial resistance in H. pylori management. Poor medication adherence demonstrated the strongest association with eradication failure, highlighting the critical importance of patient education and regimen completion.

Higher body weight additionally predicted treatment failure across regimens, an observation that may reflect altered pharmacokinetics, insufficient antibiotic exposure or larger intragastric bacterial burden. This raises important questions regarding whether weight-adjusted treatment strategies may eventually be necessary in selected populations.

Mechanistically, vonoprazan’s potent and sustained acid suppression likely enhances antibiotic stability and bacterial susceptibility by maintaining higher intragastric pH compared with traditional proton pump inhibitors. Nevertheless, this pharmacologic advantage alone was insufficient to fully overcome antimicrobial resistance when dual therapy was used.

The strong performance of the rabeprazole reverse hybrid regimen is also noteworthy. Hybrid therapies sequentially combine dual and quadruple-type approaches to maximize bacterial eradication while balancing antibiotic exposure, and this strategy continues to demonstrate robust efficacy in Asian populations.

Clinically, the findings suggest that empiric vonoprazan dual therapy should be used cautiously in areas with moderate-to-high clarithromycin resistance. Vonoprazan triple therapy or reverse hybrid regimens currently appear more reliable for achieving acceptable first-line eradication thresholds.

The study further reinforces the broader principle that modern H. pylori treatment strategies must increasingly integrate regional resistance epidemiology, adherence optimization and individualized regimen selection rather than relying on universally applied empiric protocols.

Overall, this randomized multicenter trial demonstrates that vonoprazan triple therapy and rabeprazole reverse hybrid therapy provide superior first-line H. pylori eradication compared with vonoprazan high-dose dual therapy. The results emphasize the persistent impact of clarithromycin resistance and support continued preference for combination regimens capable of consistently achieving high eradication success.